CHELMSFORD, Mass., Dec. 8, 2020 /PRNewswire/ — Brooks Automation, Inc. (Nasdaq:BRKS) announced today with great sadness that Mr. A. Clinton Allen, Director, passed away unexpectedly on December 6, 2020. Mr. Allen served on Brooks’ Board of Directors since 2003. He was 76. “We are all saddened by the sudden passing of our friend and longtime board member,... Read more
Roche today announced that new data on its investigational T-cell engaging bispecific antibodies, mosunetuzumab, glofitamab and cevostamab, were presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, from 5-8 December 2020, showing encouraging activity across multiple types of blood cancer. Read more
Single test for SARS-CoV-2, influenza (flu) A/B and RSV can detect and differentiate between diseases with similar clinical symptoms Read more
To keep pace with the rapid growth of the Chinese market for scientific instruments, WITec’s representative office in Beijing has moved to a larger space, now in the Air China Plaza Tower. Our new location features a dedicated equipment demonstration laboratory where visitors can experience our latest technologies in person, and see the advantages they... Read more
Basel, 07 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced longer-term data from the pivotal phase Ib/II GO29365 study, including data from a single-arm extension cohort of 106 additional patients, which show the benefit of Polivy® (polatuzumab vedotin) plus bendamustine and MabThera®/Rituxan® (rituximab) (BR) in people with relapsed or refractory (R/R) diffuse... Read more
Basel, 7 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from a new analysis of pooled, three-year follow-up data of 401 people with haemophilia A from the pivotal HAVEN 1-4 studies, which reinforce the long-term efficacy and safety profile of Hemlibra® (emicizumab).[1] These data, from adults, adolescents and children with haemophilia... Read more
Basel, 5 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from the pivotal phase III MURANO and CLL14 studies support the efficacy of fixed-duration, chemotherapy-free Venclexta®/Venclyxto® (venetoclax)-based combinations in certain people with chronic lymphocytic leukaemia (CLL) and provide more evidence on the potential value of minimal residual disease (MRD).... Read more